CM
ALLO icon

Caption Management’s Allogene Therapeutics ALLO Stock Holding History

Caption Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,000
Closed -$21.9K – 1404
2025
Q1 		$21.9K Hold
15,000
– – ﹤0.01% 1413
2024
Q4 		$31.9K Buy
+15,000
New +$37K ﹤0.01% 1387
2023
Q2 		– Sell
-74,900
Closed -$370K – 1073
2023
Q1 		$370K Buy
74,900
+59,900
+399% +$384K 0.01% 846
2022
Q4 		$94.3K Buy
+15,000
New +$139K ﹤0.01% 1136
2021
Q3 		– Sell
-14,600
Closed -$380K – 1474
2021
Q2 		$380K Buy
+14,600
New +$416K 0.01% 1100
2020
Q3 		– Sell
-1,400
Closed -$60K – 1007
2020
Q2 		$60K Sell
1,400
-10,600
-88% -$383K ﹤0.01% 861
2020
Q1 		$234K Sell
12,000
-6,455
-35% -$154K 0.01% 677
2019
Q4 		$480K Buy
+18,455
New +$508K 0.02% 632

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caption Management's ALLO Position: Q2 2025 in Review

Caption Management sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 15,000 shares — an estimated $21.9K sold.

Caption Management first reported a position in ALLO in Q4 2019 and held it in 8 quarters. The position peaked at $480K in Q4 2019. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

  • Caption Management reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Caption Management sold 15,000 Allogene Therapeutics shares in Q2 2025, an estimated $21.9K.
  • Caption Management first reported a position in Allogene Therapeutics in Q4 2019 and held it in 8 quarters.
  • Caption Management's Allogene Therapeutics position peaked at $480K in Q4 2019.
  • 158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Caption Management's 13F filing for Q2 2025, filed 14 Aug 2025.